EC Number   |
Inhibitors |
Structure |
|---|
   7.2.2.3 | (3beta,22alpha,25R)-26-(beta-D-glucopyranosyloxy)-2-methoxyfurost-5-en-3-yl O-D-apio-beta-D-furanosyl-(1-2)-O-[6-deoxy-alpha-L-mannopyranosyl-(1-4)]-beta-D-glucopyranoside |
- |
   |
| 7.2.2.3 | (3beta,22alpha,25R)-spirostan-3-yl O-D-apio-beta-D-furanosyl-(1-2)-O-[6-deoxy-alpha-L-mannopyranosyl-(1-4)]-beta-D-glucopyranoside |
- |
|
| 7.2.2.3 | 5-(N,N'-hexamethylene)-amiloride |
- |
|
| 7.2.2.3 | 5-(N-ethyl-N-isopropyl)-amiloride |
- |
|
| 7.2.2.3 | 7-Chloro-4-nitrobenzo-2-oxa-1,3-diazole |
- |
|
| 7.2.2.3 | adenosine |
inhibits independently of the A3 receptor |
|
| 7.2.2.3 | angiotensin II |
angiotensin II has an activating and regulatory role for Na+-ATPase activity in healthy rats, and angiotensin II links the enzyme activity to hypertension in spontaneously hypertensive rats, where it has an inhibitory effect on Na+-ATPase activity. The Ang II inhibitory effect is completely reversed by a specific antagonist of AT2 receptor, PD123319. Ang II interacts with different receptors in spontaneously hypertensive rats and WKY wild-type rats |
|
| 7.2.2.3 | ATPgammaS |
- |
|
| 7.2.2.3 | atrial natriuretic peptide |
selectively inhibits the enzyme in basolateral membranes of kidney proximal tubules by activation of guanylyl cyclase activity, which is inhibited by LY83583 |
|
| 7.2.2.3 | benzamil |
- |
|
